N
Nuvalent
Targeted small-molecule cancer therapies for kinase-driven cancers
About Nuvalent
Nuvalent is a biotechnology company focused on developing targeted therapies for cancer patients. The company specializes in creating innovative small molecules that precisely inhibit kinase targets, which are proteins involved in the growth and spread of cancer cells. Nuvalent's primary focus is on non-small cell lung cancer (NSCLC) with ROS1 positive and ALK positive mutations, but it also has multiple discovery-stage research programs in progress.
Read full description
Nuvalent operates in the oncology market, serving patients who have not responded well to existing treatments. The company partners with healthcare providers to identify patient needs and the limitations of current therapies. By leveraging its deep expertise in chemistry and structure-based drug discovery, Nuvalent aims to overcome the dual challenges of resistance and selectivity in cancer treatment.
The business model is centered around research and development, with revenue generated through the commercialization of its therapies, either independently or through partnerships with larger pharmaceutical companies.
At a glance
- Founded
- 2017
- Headquarters
- Cambridge, United States
- Listing
- IPO 2021
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Research & analysis
Latest news
Press, funding announcements and product moves mentioning Nuvalent.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
Deerfield
Bain Capital Life Sciences
Wellington Management
Boxer Capital
Fidelity Investments
Driehaus Capital Management
Avoro Capital Advisors
Venrock
Viking Global Investors
Janus Henderson Investors
Logos Capital
Fairmount Funds Management
Series B and later12 investors entered at this stage
- BCBoxer Capital
- FMFairmount Funds Management
- VIViking Global Investors
- HUHarvard University
- LCLogos Capital
- Wellington Management
- Janus Henderson Investors
- Venrock
- AAAvoro Capital Advisors
- Fidelity Investments
- DMDriehaus Capital Management
- BSBain Capital Life Sciences
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
11 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nuvalent on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nuvalent on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.